López-Tinoco, CristinaJiménez-Blázquez, José LuisLarrán-Escandón, LauraRoca-Rodríguez, María Del MarBugatto, FernandoAguilar-Diosdado, Manuel2023-02-082023-02-082019-11-27http://hdl.handle.net/10668/14757To evaluate the effectiveness of the different insulin therapies on obstetrics-fetal outcomes in women with pregestational diabetes mellitus. We enrolled 147 pregnant women with pre-existing type 1 or 2 diabetes mellitus. Clinical and biochemical parameters were analysed in relation to obstetric and fetal outcomes. 14.2% received treatment with Neutral Protamine Hagedorn insulin and short-acting insulin analogues; 19% with premixed human insulin; 40.1% with insulin glargine and lispro, 6.2% with detemir and aspart and 20% with continuous subcutaneous insulin infusion. All 5 types of treatment achieved a reduction of the mean HbA1c during pregnancy (p = 0.01). Pre-pregnancy care was carried out for 48% of patients. We found no statistically significant differences between the different insulin therapies and the obstetric-fetal outcomes. In conclusión, the different insulin therapies used in patients with pregestational diabetes mellitus does not seem to affect obstetric-fetal outcomes.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/AdultDiabetes MellitusDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetes, GestationalDrug CombinationsFemaleGlycated HemoglobinHumansInsulinInsulin DetemirInsulin GlargineInsulin LisproInsulin, Long-ActingPregnancyPregnancy Outcomeresearch article31776421open access10.1038/s41598-019-54164-42045-2322PMC6881342https://www.nature.com/articles/s41598-019-54164-4.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881342/pdf